Cutting Edge Therapies for Cancer in the 21st Century

Targeting Interleukin-6 for the Treatment of Castration-Resistant Prostate Cancer

Author(s): Sonia Godoy-Tundidor, Sucharitha Balasubramaniam, Ana Romero- Weaver and Zoran Culig

Pp: 219-252 (34)

Doi: 10.2174/9781608058808114010011

* (Excluding Mailing and Handling)

Abstract

The existence of a crosstalk between the androgen receptor (AR) pathway and interleukin-6 (IL-6) signaling in prostate cancer (PCa) is broadly recognized. IL-6 activates the AR in a ligand-independent manner leading to the transcription of prostatespecific antigen (PSA), the most widely used marker for the detection and monitoring of PCa. IL-6 expression is increased in the malignant epithelium of prostate cancer patients and its levels are enhanced in the plasma of patients with late-stage disease. Interestingly, IL-6 is able to shift from being a paracrine growth inhibitor to an autocrine growth stimulator in PCa cells. Hence, IL-6 has been implicated in the progression towards castration-resistant prostate cancer (CRPC), in which elevated levels are indicative of poor prognosis and predict resistance to chemotherapy with taxanes. We will depict here the IL-6 signaling pathway and its contribution to PCa. For this purpose, we will portray the molecular events that prompted the origin of LNCaPIL- 6+ cells, a model of advanced PCa, upon chronic exposure to IL-6. We will also examine the similarities between LNCaP-IL-6+ cells and late-stage prostatic carcinoma. In addition, we will reveal the effect of CNTO 328, a chimeric monoclonal antibody targeting IL-6, in LNCaP-IL-6+ cells, as well as discuss the latest results from clinical trials with CNTO 328 in CRPC patients. Finally, we will speculate on the possibility, not yet investigated, of administering CNTO 328 to patients before the onset of CRPC.


Keywords: Interleukin-6 (IL-6), prostate cancer, castration-resistant prostate cancer, androgen deprivation therapy, androgen receptor, androgen, antiandrogen, JAK/STAT, MAP kinase, VEGF, retinoblastoma, clinical trials, prostate specific antigen (PSA).

Related Journals
Related Books
© 2022 Bentham Science Publishers | Privacy Policy